Advertisement

Survival Outcomes and Patterns of Management for Anal Adenocarcinoma

  • Gary D. Lewis
  • Waqar Haque
  • E. Brian Butler
  • Bin S. TehEmail author
Colorectal Cancer
  • 27 Downloads

Abstract

Background

Anal adenocarcinoma (AA) is a rare histologic subtype of anal cancer believed to have worse outcomes than anal squamous cell carcinoma (AS). This study aimed to examine practice patterns and treatment outcomes for this rare subtype using the National Cancer Data Base (NCDB).

Methods

Patients who had new diagnoses of anal cancer treated with chemoradiation were selected from the NCDB from 2004 to 2015. The patients were divided into two histologic groups (AA or AS). Statistics included the Chi square test to analyze categorical proportions in demographic information, Kaplan–Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS.

Results

The study analyzed 24,461 patients. Compared with AS patients, AA patients were more likely to be male, to present with a higher cancer stage, to be older (> 65 years), and to undergo surgery with an abdominoperineal resection (APR). The median OS was 72.5 months for the AA patients and 143.8 months for the AS patients (P < 0.001). Survival was longer for the AA patients undergoing APR within 6 months after chemoradiation (CRT) than for the AA patients who had an APR 6 months after CRT (88.3 vs. 58.1 months; P < 0.001). In the multivariable analysis, the factors associated with worse survival included adenocarcinoma subtype, age of 55 years or older, male gender, T stage of 3 or higher, comorbidity score of 1 or higher, lower income, and treatment at a nonacademic institution.

Conclusions

In this largest study of anal adenocarcinoma to date, trimodality therapy was associated with better survival than chemoradiation alone.

Notes

Disclosure

There are no conflicts of interest.

Supplementary material

10434_2019_7202_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68:7–30.  https://doi.org/10.3322/caac.21442.CrossRefGoogle Scholar
  2. 2.
    Leonard D, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg. 2011;24:54–63.  https://doi.org/10.1055/s-0031-1272824.CrossRefGoogle Scholar
  3. 3.
    Franklin RA, Giri S, Valasareddy P, Lands LT, Martin MG. Comparative survival of patients with anal adenocarcinoma, squamous cell carcinoma of the anus, and rectal adenocarcinoma. Clin Colorectal Cancer. 2016;15:47–53.  https://doi.org/10.1016/j.clcc.2015.07.007.CrossRefGoogle Scholar
  4. 4.
    Anwar S, Welbourn H, Hill J, Sebag-Montefiore D. Adenocarcinoma of the anal canal: a systematic review. Color Dis. 2013;15:1481–8.  https://doi.org/10.1111/codi.12325.CrossRefGoogle Scholar
  5. 5.
    Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1974;17:354–56.  https://doi.org/10.1007/bf02586980.CrossRefGoogle Scholar
  6. 6.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.  https://doi.org/10.1245/s10434-007-9747-3.CrossRefGoogle Scholar
  7. 7.
    Lewis GD, Haque W, Verma V, Butler EB, Teh BS. The role of adjuvant radiation therapy in locally advanced bladder cancer. Bladder Cancer. 2018;4:205–13. https://doi.org/10.3233/blc-180163.CrossRefGoogle Scholar
  8. 8.
    Lewis GD, Xing Y, Patel T, et al. Abstract P6-09-06: The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast: an analysis from the National Cancer Data Base. 2018.Google Scholar
  9. 9.
    Lewis GD, Dalwadi SM, Farach A, Butler EB, Teh BS. (P35) The role of adjuvant radiotherapy in the treatment of pleural mesothelioma. Int J Radiat Oncol. 2018;101:E34.  https://doi.org/10.1016/j.ijrobp.2018.02.123.CrossRefGoogle Scholar
  10. 10.
    Lewis GD, Xing Y, Patel T, et al. (P008) Impact of radiotherapy on lymphotropic invasive micropapillary carcinoma of the breast: an analysis from the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2017;98:E17.CrossRefGoogle Scholar
  11. 11.
    Haque W, Lewis GD, Verma V, Darcourt JG, Butler EB, Teh BS. The role of adjuvant chemotherapy in locally advanced bladder cancer. Acta Oncol Madr. 2018;57:509–15.  https://doi.org/10.1080/0284186x.2017.1415461.CrossRefGoogle Scholar
  12. 12.
    Haque W, Verma V, Lewis GD, Lo SS, Butler EB, Teh BS. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol. 2018;https://doi.org/10.2217/fon-2017-0536.Google Scholar
  13. 13.
    Brower JV, Chen S, Bassetti MF, et al. Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys. 2016;96:985–93.  https://doi.org/10.1016/j.ijrobp.2016.08.016.CrossRefGoogle Scholar
  14. 14.
    Monastyrska E, Hagner W, Jankowski M, Głowacka I, Zegarska B, Zegarski W. Prospective assessment of the quality of life in patients treated surgically for rectal cancer with lower anterior resection and abdominoperineal resection. Eur J Surg Oncol. 2016;42:1647–53.  https://doi.org/10.1016/j.ejso.2016.07.007.CrossRefGoogle Scholar
  15. 15.
    Belkacémi Y, Berger C, Poortmans P, et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2003;56:1274–83.  https://doi.org/10.1016/s0360-3016(03)00277-3.CrossRefGoogle Scholar
  16. 16.
    Joon DL, Chao MW, Ngan SY, Joon ML, Guiney MJ. Primary adenocarcinoma of the anus: a retrospective analysis. Int J Radiat Oncol Biol Phys. 1999;45:1199–205.  https://doi.org/10.1016/s0360-3016(99)00267-9.CrossRefGoogle Scholar
  17. 17.
    Papagikos M, Crane CH, Skibber J, et al. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys. 2003;55:669–78. http://www.ncbi.nlm.nih.gov/pubmed/12573754. Accessed 18 Mar 2018.
  18. 18.
    Kounalakis N, Artinyan A, Smith D, Mojica-Manoso P, Paz B, Lai LL. Abdominal perineal resection improves survival for nonmetastatic adenocarcinoma of the anal canal. Ann Surg Oncol. 2009;16:1310–15.  https://doi.org/10.1245/s10434-009-0392-x.CrossRefGoogle Scholar
  19. 19.
    Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009;52:1375–80.  https://doi.org/10.1007/dcr.0b013e3181a79589.CrossRefGoogle Scholar
  20. 20.
    Su Z, Guo Z-W, Mao Y-P, et al. Anal adenocarcinoma requires prophylactic inguinal nodal treatment: results from a single Chinese institution. J Cancer. 2017;8:1097–102.  https://doi.org/10.7150/jca.17513.CrossRefGoogle Scholar
  21. 21.
    Beal KP, Wong D, Guillem JG, et al. Primary adenocarcinoma of the anus treated with combined modality therapy. Dis Colon Rectum. 2003;46:1320–4.  https://doi.org/10.1007/s10350-004-6740-9.CrossRefGoogle Scholar
  22. 22.
    Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal. Cancer. 1999;85:1686–93.  https://doi.org/10.1002/(sici)1097-0142(19990415)85:8%3c1686::aid-cncr7%3e3.0.co;2-7.CrossRefGoogle Scholar
  23. 23.
    Basik M, Rodriguez-Bigas MA, Penetrante R, Petrelli NJ. Prognosis and recurrence patterns of anal adenocarcinoma. Am J Surg. 1995;169:233–7.  https://doi.org/10.1016/s0002-9610(99)80143-3.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Gary D. Lewis
    • 1
    • 2
  • Waqar Haque
    • 2
  • E. Brian Butler
    • 2
  • Bin S. Teh
    • 2
    Email author
  1. 1.Department of Radiation OncologyUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Department of Radiation Oncology, Cancer Center and Research Institute, Weil Cornell Medical CollegeHouston Methodist HospitalHoustonUSA

Personalised recommendations